Kirkland Assists ImmuneOnco Biopharmaceuticals On Its New H-Share Placing.

Kirkland & Ellis represented the sole overall coordinator and placing agent, China International Capital Corporation Hong Kong Securities Limited, in connection with the new H-share placing (the “H-Share Placing”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco Biopharmaceuticals”) (HKSE: 1541) under the general mandate granted by shareholders earlier this year. 
 
The H-Share Placing was announced on November 21, 2024, and completed on November 28, 2024. An aggregate of 33,150,000 new H Shares, representing approximately 8.14% of the enlarged issued share capital of ImmuneOnco Biopharmaceuticals have been successfully placed to not less than six independent placees. The gross proceeds received by ImmuneOnco Biopharmaceuticals from the H-Share Placing are approximately HK$234 million.
 
ImmuneOnco Biopharmaceuticals is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It stands out as one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems.
 
Read the announcement 
 
The Kirkland team included corporate/capital markets lawyers Mengyu Lu and Samantha Peng, legal manager Sierra Tao, and international legal consultants Kaiwen Xu and Ashley Guo.